Fig. 2
From: Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis
Effect of Tofacitinib on tube formation of HC-ECs. A–C Representative image of Matrigel angiogenesis assays of untreated (UT) HC-ECs (A), HC-ECs treated with 20 ng/ml of VEGF (B) and HC-ECs treated with 20 ng/ml of VEGF and 1 μM of tofacitinib (C). D–F Quantification of total length (D), total branching length (E) and junctions (F) of the tubes obtained in the in matrigel assay. In HC-ECs, the stimulation with VEGF induced a significant increase in the total tube length, the total branching length and the number of junctions, when compared to UT HC-ECs. In HC-ECs treated with both tofacitinib and VEGF, the total tube length, the total branching length and the number of junctions were significantly decreased, when compared with HC-ECs treated with VEGF. The histograms showed the median and the range of total tube length, total branching length and number of junctions in matrigel assay (*p ≤ 0.03; **p = 0.007)